Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BTK Inhibitor Calms Pemphigus Vulgaris With Low-Dose Steroids

Publish date:: April 1, 2019

Key clinical point: PRN1008 improved disease activity and induced remission in pemphigus.

Major finding: At the end of the 24-week study, 70% experienced a clinical response and 25% experienced remission.

Study details: The open-label study comprised 27 patients.

Disclosures: Principia Biopharma is developing the molecule and sponsored the study. Dr. Murrell designed the study and reported a financial relationship with Principia, as well as with numerous other pharmaceutical companies.

Citation:

Murrell D et al. AAD 2019, Session S034.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Autoimmune Diseases

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Slow taper off antimalarial is best to avoid lupus flare during remission,

Transcutaneous VNS on the ear shows positive effects in lupus pilot trial,

New lupus classification criteria perform well in children, young adults,

Phone outreach intervention feasible to reduce SLE readmissions,